Dosing & Uses
Dosage Forms & Strengths
piperacillin/tazobactam
injection, lyophilized powder for reconstitution
- (2g/250mg)/vial: 2.25g
- (3g/375mg)/vial: 3.375g
- (4g/500mg)/vial: 4.5g
- (36g/4.5g)/vial: 40.5g
premix bag
- 2.25g/50mL
- 3.375g/50mL
- 4.5g/100mL
Intra-abdominal Infections
Indicated for treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B fragilis, B ovatus, B thetaiotaomicron, or B vulgatus
3.375 g IV q6hr (totaling 13.5 g [12 g piperacillin/1.5 g tazobactam]) for 7-10 days
Nosocomial Pneumonia
Indicated for treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa
Nosocomial pneumonia caused by P aeruginosa should be treated in combination with an aminoglycoside
4.5 g IV q6hr (totaling 18 g [16 g piperacillin/2 g tazobactam]) for 7-14 days; continue aminoglycoside in P. aeruginosa patients
Skin and Skin Structure infections
Indicated for treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus
3.375 g IV q6hr (totaling 13.5 g [12 g piperacillin/1.5 g tazobactam]) for 7-10 days
Female Pelvic Infections
Indicated in treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of E coli
3.375 g IV q6hr (totaling 13.5 g [12 g piperacillin/1.5 g tazobactam]) for 7-10 days
Community-acquired Pneumonia
Indicated for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of H influenzae
3.375 g IV q6hr (totaling 13.5 g [12 g piperacillin/1.5 g tazobactam]) for 7-10 days
Dosage Modifications
Renal impairment
-
All indications except nosocomial pneumonia
- CrCl >40 mL/min: 3.375 g IV q6hr
- CrCl 20-40 mL/min (without hemodialysis): 2.25 IV q6hr
- CrCl <20 mL/min (without hemodialysis): 2.25 g IV q8hr
- Hemodialysis: 2.25 g IV q12hr; administer an additional dose of 0.75 g (0.67 g piperacillin/0.08 g tazobactam) following each dialysis period on hemodialysis days
- CAPD: 2.25 g IV q12hr
-
Nosocomial pneumonia
- CrCl >40 mL/min: 4.5 g IV q6hr
- CrCl 20-40 mL/min (without hemodialysis): 3.375 IV q6hr
- CrCl <20 mL/min (without hemodialysis): 2.25 g IV q6hr
- Hemodialysis: 2.25 g IV q8hr; administer an additional dose of 0.75 g (0.67 g piperacillin/0.08 g tazobactam) following each dialysis period on hemodialysis days
- CAPD: 2.25 g IV q8hr
Hepatic impairment
- Dosage adjustment not warranted in patients with hepatic cirrhosis
Cystic fibrosis patients
- As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients
Dosing Considerations
Administering drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases risk of development of drug-resistant bacteria
When culture and susceptibility information are available, consider selecting or modifying antibacterial therapy
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy
Dosage Forms & Strengths
piperacillin/tazobactam
injection, lyophilized powder for reconstitution
- (2g/250mg)/vial: 2.25g
- (3g/375mg)/vial: 3.375g
- (4g/500mg)/vial: 4.5g
- (36g/4.5g)/vial: 40.5g
premix bag
- 2.25g/50mL
- 3.375g/50mL
- 4.5g/100mL
Intra-abdominal Infections
Indicated for treatment of appendicitis (complicated by rupture or abscess) and/or peritonitis in adult and pediatric patients aged ≥2 months caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B fragilis, B ovatus, B thetaiotaomicron, or B vulgatus
<2 months: Safety and efficacy not established
2-9 months
>9 months
- ≤40 kg: 112.5 mg/kg (100 mg piperacillin/12.5 mg tazobactam) IV q8hr
- >40 kg: 3.375 g IV q6hr (totaling 13.5 g [12 g piperacillin/1.5 g tazobactam]) for 7-10 days
Nosocomial Pneumonia
Indicated for treatment of nosocomial pneumonia (moderate to severe) in adult and pediatric patients aged ≥2 months caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa
Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside
<2 months: Safety and efficacy not established
2-9 months
>9 months
- ≤40 kg: 112.5 mg/kg (100 mg piperacillin/12.5 mg tazobactam) IV q6hr
- >40 kg: 4.5 g IV q6hr (totaling 18 g [16 g piperacillin/2 g tazobactam]) for 7-14 days
Dosage Modifications
Renal impairment
- Dosage in pediatric patients with renal impairment has not been determined
Hepatic impairment
- Dosage adjustment not warranted in patients with hepatic cirrhosis
Cystic fibrosis patients
- As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of fever and rash in patients with cystic fibrosis
Dosing Considerations
Administering drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases risk of development of drug-resistant bacteria
When culture and susceptibility information are available, consider selecting or modifying antibacterial therapy
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy
Because of limitations of available strengths and administration requirements (ie, administration of fractional doses not recommended) of injection supplied in GALAXY Containers; to avoid unintentional overdose, this product not recommended for use if a dose of injection in GALAXY Containers that does not equal 2.25 g, 3.375 g, or 4.5 g is required and an alternative formulation of the drug should be considered
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (12)
- antithrombin alfa
piperacillin increases effects of antithrombin alfa by pharmacodynamic synergism. Avoid or Use Alternate Drug.
- antithrombin III
piperacillin increases effects of antithrombin III by pharmacodynamic synergism. Avoid or Use Alternate Drug.
- argatroban
piperacillin will increase the level or effect of argatroban by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity
- BCG vaccine live
piperacillin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until antibiotic treatment complete to administer live bacterial vaccine; antibiotics may diminish therapeutic effects of BCG.
- bivalirudin
piperacillin will increase the level or effect of bivalirudin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity
- cholera vaccine
piperacillin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- dalteparin
piperacillin increases effects of dalteparin by anticoagulation. Avoid or Use Alternate Drug. Piperacillin can inhibit platelet aggregation.
- enoxaparin
piperacillin increases effects of enoxaparin by anticoagulation. Avoid or Use Alternate Drug. Piperacillin can inhibit platelet aggregation.
- heparin
piperacillin will increase the level or effect of heparin by anticoagulation. Avoid or Use Alternate Drug. piperacillin can inhibit platelet aggregation
- microbiota oral
piperacillin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. .
- omadacycline
omadacycline decreases effects of piperacillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Tetracyclines may interfere with the bactericidal action of penicillins. Monitor for decreased therapeutic effects of penicillins if concomitantly used with a tetracycline.
- sarecycline
sarecycline decreases effects of piperacillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Tetracyclines may interfere with the bactericidal action of penicillins. Monitor for decreased therapeutic effects of penicillins if concomitantly used with a tetracycline.
Monitor Closely (18)
- azithromycin
azithromycin decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- bazedoxifene/conjugated estrogens
piperacillin will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- chloramphenicol
chloramphenicol decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- clarithromycin
clarithromycin decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- demeclocycline
demeclocycline decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- dichlorphenamide
dichlorphenamide and piperacillin both decrease serum potassium. Use Caution/Monitor.
- doxycycline
doxycycline decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- erythromycin base
erythromycin base decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- erythromycin ethylsuccinate
erythromycin ethylsuccinate decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- erythromycin lactobionate
erythromycin lactobionate decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- erythromycin stearate
erythromycin stearate decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- minocycline
minocycline decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- probenecid
probenecid will increase the level or effect of piperacillin by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.
- sodium picosulfate/magnesium oxide/anhydrous citric acid
piperacillin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
- tetracycline
tetracycline decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.
- vancomycin
piperacillin increases toxicity of vancomycin by unspecified interaction mechanism. Use Caution/Monitor. Monitor kidney function in patients concomitantly administered with piperacillin and vancomycin.
- vecuronium
piperacillin increases toxicity of vecuronium by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Neuromuscular blockade may be prolonged.
- warfarin
piperacillin, warfarin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Platelet dysfunction occurs with extended-spectrum penicillins in varying degrees. Monitor INR and adjust warfarin dose if needed.
Minor (15)
- amikacin
piperacillin increases effects of amikacin by pharmacodynamic synergism. Minor/Significance Unknown.
- aspirin
piperacillin, aspirin. Either increases effects of the other by receptor binding competition. Minor/Significance Unknown. Salicylic acid could be displaced from protein binding sites or it could itself displace other protein-bound drugs and result in an enhanced effect of the displaced drug.
- aspirin rectal
piperacillin will increase the level or effect of aspirin rectal by plasma protein binding competition. Minor/Significance Unknown. Salicylic acid could be displaced from protein binding sites or it could itself displace other protein-bound drugs and result in an enhanced effect of the displaced drug
- aspirin/citric acid/sodium bicarbonate
piperacillin will increase the level or effect of aspirin/citric acid/sodium bicarbonate by plasma protein binding competition. Minor/Significance Unknown. Salicylic acid could be displaced from protein binding sites or it could itself displace other protein-bound drugs and result in an enhanced effect of the displaced drug
- chlorothiazide
chlorothiazide increases levels of piperacillin by decreasing renal clearance. Minor/Significance Unknown.
- choline magnesium trisalicylate
piperacillin will increase the level or effect of choline magnesium trisalicylate by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown. Salicylate saltscould be displaced from binding sites or could displace other highly protein-bound drugs such as penicillins
- gentamicin
piperacillin increases effects of gentamicin by pharmacodynamic synergism. Minor/Significance Unknown.
- hydrochlorothiazide
hydrochlorothiazide increases levels of piperacillin by decreasing renal clearance. Minor/Significance Unknown.
- ibuprofen IV
piperacillin will increase the level or effect of ibuprofen IV by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- meclofenamate
piperacillin will increase the level or effect of meclofenamate by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- neomycin PO
piperacillin increases effects of neomycin PO by pharmacodynamic synergism. Minor/Significance Unknown.
- rose hips
rose hips will increase the level or effect of piperacillin by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- streptomycin
piperacillin increases effects of streptomycin by pharmacodynamic synergism. Minor/Significance Unknown.
- tobramycin
piperacillin increases effects of tobramycin by pharmacodynamic synergism. Minor/Significance Unknown.
- willow bark
piperacillin will increase the level or effect of willow bark by acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown.
Adverse Effects
>10%
Diarrhea (7-11%)
1-10%
Constipation (1-8%)
Headache (1-8%)
Insomnia (4-7%)
Nausea (2-7%)
Fever (2-5%)
Oral candidiasis (2-4%)
Rash (2-4%)
Vomiting (2-4%)
Dyspepsia (3%)
Pruritus (3%)
Pain (2-3%)
Hypertension (2%)
Leukopenia (1%)
Thrombocytopenia (1.4%)
<1%
Anaphylaxis
Agranulocytosis
Thrombocytopenia
Eosinophilia, melena
Leukopenia
Positive Coombs test
Prolonged PT and PTT
Transient LFT and creatinine elevations
Seizure
Pulmonary edema
Pulmonary embolism
Postmarketing Reports
Gastrointestinal: Hepatitis, jaundice
Hematologic: Hemolytic anemia, agranulocytosis, pancytopenia
Immune: Hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock)
Renal: Interstitial nephritis
Skin and appendages: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, dermatitis exfoliative
Respiratory, thoracic and mediastinal disorders: Epistaxis, eosinophilic pneumonia
Psychiatric disorders: Delirium
Drug reaction with eosinophilia and systemic symptoms (DRESS)
Acute generalized exanthematous pustulosis
Hemophagocytic lymphohistiocytosis (HLH)
Warnings
Contraindications
Allergy to penicillins, cephalosporins, imipenem, beta-lactamase inhibitors
Cautions
Risk of bleeding complications, especially in renal impairment; discontinue if thrombocytopenia or bleeding occurs
Leukopenia/neutropenia associated with prolonged therapy; periodic assessment of hematopoietic function should be performed, especially with prolonged therapy that is ≥ 21 days
Serious skin reactions reported, including Stevens-Johnson syndrome and toxic epidermal necrolysis, generalized exanthematous pustulosis; discontinue if reaction occurs
Monitor renal, hepatic, and especially hematopoietic functions during prolonged treatment
Prolonged use may result in fungal or bacterial superinfection
Administering drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases risk of development of drug-resistant bacteria
Clostridium difficile associated diarrhea (CDAD) reported; if CDAD suspected or confirmed, may need to discontinue ongoing antibacterial drug use not directed against C. difficile; appropriate fluid and electrolyte management, protein supplementation may need to be implemented; antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated
Increased frequency of rash and fever reported in cyctic fibrosis patients receiving piperacillin
Risk of seizures may increase in patients with history of seizures when administered at higher than recommended doses given IV in the presence of renal impairment
Consider sodium content (2.79 mEq/g piperacillin) in patients requiring sodium restriction
Perform periodic electrolyte determinations in patients with low potassium reserves and who are receiving cytotoxic therapy or diuretics and consider possibility of hypokalemia in patients who have potentially low potassium reserves
Increased frequency of fever and rash reported in patients with cystic fibrosis receiving piperacillin
Use caution in patients with renal impairment or underdeveloped kidneys due to sodium load and adverse effects of high serum concentrations of penicillin; dose adjustment may be necessary
Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given IV (particularly in presence of renal failure); closely monitor patients with renal impairment or seizure disorders for signs and symptoms of neuromuscular excitability or convulsions (seizures)
Cases of hemophagocytic lymphohistiocytosis (HLH) reported in pediatric and adult patients; signs and symptoms of HLH may include fever, rash, lymphadenopathy, hepatosplenomegaly, and cytopenia; if HLH is suspected, discontinue therapy immediately and institute appropriate management
Drug interaction overview
- Piperacillin when used concomitantly with vecuronium has been implicated in prolongation of neuromuscular blockade of vecuronium
- Treatment could produce the same phenomenon if given along with vecuronium; due to their similar mechanism of action, it is expected that neuromuscular blockade produced by any of the non-depolarizing neuromuscular blockers could be prolonged in the presence of piperacillin
- Monitor for adverse reactions related to neuromuscular blockade
Pregnancy & Lactation
Pregnancy
Piperacillin and tazobactam cross placenta in humans
Insufficient data available with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage
Animal data
- No fetal structural abnormalities observed in rats or mice when drug administered IV during organogenesis at doses 1 to 2 times and 2 to 3 times human dose of piperacillin and tazobactam, respectively; based on body-surface area (mg/m2)
- Fetotoxicity in presence of maternal toxicity was observed in developmental toxicity and peri/postnatal studies conducted in rats (intraperitoneal administration prior to mating and throughout gestation or from gestation day 17 through lactation day 21) at doses less than maximum recommended human daily dose based on body-surface area (mg/m2)
Lactation
Piperacillin is excreted in human milk; tazobactam concentrations in human milk have not been studied
No information available on effects of piperacillin and tazobactam on breastfed child or on milk production
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antipseudomonal penicillin plus beta-lactamase inhibitor; inhibits biosynthesis of cell wall mucopeptide synthesis by binding to 1 or more of the penicillin-binding proteins and is effective during active-multiplication stage
Absorption
Peak plasma concentration
- Piperacillin: 134 mcg/mL (2.25-g dose); 242 mcg/mL (3.375-g dose); 298 mcg/mL (4.5-g dose)
- Tazobactam: 15 mcg/mL (2.25-g dose); 24 mcg/mL (3.375-g dose); 34 mcg/mL (4.5-g dose)
AUC
- Piperacillin: 131 mcg⋅hr/mL (2.25-g dose); 242 mcg⋅hr/mL (3.375-g dose); 322 mcg⋅hr/mL (4.5-g dose)
- Tazobactam: 16 mcg⋅hr/mL (2.25-g dose); 25 mcg⋅hr/mL (3.375-g dose); 39.8 mcg⋅hr/mL (4.5-g dose)
Distribution
Protein bound: ~30%
Lungs, intestinal mucosa, skin, muscle, uterus, ovary, prostate, gallbladder, and bile; low CSF penetration in noninflamed meninges
Metabolism
Hepatic to desethyl metabolite (piperacillin) and inactive metabolite (tazobactam)
Elimination
Half-life: 0.7-1.2 hr
Excretion
- Piperacillin: Urine (68%); feces (10-20%)
- Tazobactam: Urine (80%)
- Both also excreted in bile
Clearance
- Piperacillin: 257 mL/min (2.25-g dose); 207 mL/min (3.375-g dose); 210 mL/min (4.5-g dose)
- Tazobactam: 258 mL/min (2.25-g dose); 251 mL/min (3.375-g dose); 206 mL/min (4.5-g dose)
Administration
IV Incompatibilities
- Do not mix with other drugs in syringe or infusion bottle since compatibility has not been established
- Not chemically stable in solutions that contain only sodium bicarbonate and solutions that significantly alter the pH
- Do not add to blood products or albumin hydrolysates
IV Compatibilities
- 0.9% NaCl
- Sterile water for injection (maximum volume: 50 mL)
- Dextran 6% in NS
- Dextrose 5%
- Lactated Ringer (compatible only with reformulated piperacillin/tazobactam containing EDTA and is compatible for coadministration via a Y-site)
- Refer to prescribing information for specific Y-site compatibility information
Reconstitution
Compatible for reconstitution
- 0.9% NaCl
- Sterile water for injection
- Dextrose 5%
- Bacteriostatic saline/parabens
- Bacteriostatic water/parabens
- Bacteriostatic saline/benzyl alcohol
- Bacteriostatic water/benzyl alcohol
Bulk vial
- Reconstitute with exactly 152 mL of compatible reconstitution diluent (final concentration: 200 mg/mL of piperacillin and 25 mg/mL of tazobactam)
- Shake well until dissolved
- Visually inspect for particulate matter and discoloration before and during administration whenever solution and container permit
IV Preparation
Premix frozen bag
- Check for minute leaks by squeezing container firmly
- If leaks are detected, discard solution as sterility may be impaired.
- Visually inspect product; components of solution may precipitate while frozen and will dissolve upon reaching room temperature with little or no agitation; agitate after solution has reached room temperature
- If after visual inspection, the solution remains cloudy or if an insoluble precipitate is noted or if any seals or outlet ports are not intact, discard the container
IV Administration
Infuse over 30 min
Storage
Unopened Vials
- Store at room temperature (20-25ºC [68-77ºF])
Premix frozen bag
- Unused: Freeze at -20ºC [-4ºF])
- Thawed bag: Refrigerate at (2-8ºC [36-46ºF]) for up to 14 days or store at room temperature (20-25ºC [68-77ºF]) for up to 24 hr; do not refreeze thawed bag
Diluted IV solutions
- Store at room temperature (20-25ºC [68-77ºF]) for up to 24 hr, or after 1 week if refrigerated (2-8ºC [36-46ºF])
Reconstituted single-dose vials or pharmacy bulk vials
- Store at room temperature (20-25vC [68-77ºF]) for up to 24 hr, or after 48 hours if refrigerated (2-8ºC [36-46ºF])
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
